David M. Spiegel - Publications

Correction to: Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study.

Journal: Kidney360

Published: April 17, 2026

The Positive Impact of Patient Education on Tenapanor Adherence in the OPTIMIZE Study.

Journal: Nephrology nursing journal : journal of the American Nephrology Nurses' Association

Published: July 07, 2025

Effectiveness of tenapanor for treating hyperphosphatemia in patients receiving dialysis: a plain language summary of the OPTIMIZE study.

Journal: Current medical research and opinion

Published: July 23, 2024

Tenapanor: A Phosphate Absorption Inhibitor for the Management of Hyperphosphatemia in Patients With Kidney Failure.

Journal: Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation

Published: April 16, 2024

Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study.

Journal: Kidney360

Published: July 07, 2023

The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: January 16, 2020

Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients.

Journal: Kidney international reports

Published: June 07, 2018

Effects of the Potassium-Binding Polymer Patiromer on Markers of Mineral Metabolism.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: April 09, 2018

Patiromer Lowers Serum Potassium When Taken without Food: Comparison to Dosing with Food from an Open-Label, Randomized, Parallel Group Hyperkalemia Study.

Journal: American journal of nephrology

Published: August 04, 2017

Calcium Balance in Chronic Kidney Disease.

Journal: Current osteoporosis reports

Published: May 06, 2017

Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.

Journal: JAMA

Published: January 18, 2017

Serum-to-dialysate potassium gradient and its association with short-term outcomes in hemodialysis patients.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: January 11, 2017